fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Dupixent as add-on treatment for moderate-to-severe asthma – Sanofi + Regeneron

Written by | 8 Jan 2022

The FDA has approved Dupixent (dupilumab), from Sanofi + Regeneron, as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.